Reviewing PerkinElmer Inc. (PKI)’s and Cytosorbents Corporation (NASDAQ:CTSO)’s results

PerkinElmer Inc. (NYSE:PKI) and Cytosorbents Corporation (NASDAQ:CTSO) compete with each other in the Medical Laboratories & Research sector. We will analyze and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PerkinElmer Inc. 96 1.91 102.96M 2.09 45.14
Cytosorbents Corporation 4 0.00 26.58M -0.65 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of PerkinElmer Inc. and Cytosorbents Corporation.


Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
PerkinElmer Inc. 106,915,887.85% 8.8% 3.8%
Cytosorbents Corporation 671,856,832.31% -165% -67.7%

Risk & Volatility

PerkinElmer Inc.’s 1.3 beta indicates that its volatility is 30.00% more volatile than that of Standard and Poor’s 500. Competitively, Cytosorbents Corporation’s 81.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 1.81 beta.


The Current Ratio and a Quick Ratio of PerkinElmer Inc. are 1.3 and 1. Competitively, Cytosorbents Corporation has 2.4 and 2.2 for Current and Quick Ratio. Cytosorbents Corporation’s better ability to pay short and long-term obligations than PerkinElmer Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for PerkinElmer Inc. and Cytosorbents Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PerkinElmer Inc. 0 5 2 2.29
Cytosorbents Corporation 0 0 1 3.00

$98.29 is PerkinElmer Inc.’s average target price while its potential downside is -3.38%. On the other hand, Cytosorbents Corporation’s potential upside is 120.75% and its average target price is $10. Based on the data shown earlier, Cytosorbents Corporation is looking more favorable than PerkinElmer Inc., analysts view.

Institutional & Insider Ownership

The shares of both PerkinElmer Inc. and Cytosorbents Corporation are owned by institutional investors at 98.2% and 26.8% respectively. 0.1% are PerkinElmer Inc.’s share owned by insiders. Competitively, Cytosorbents Corporation has 4.5% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PerkinElmer Inc. 1.31% 9.38% 12.34% 0.42% 9.42% 19.82%
Cytosorbents Corporation -0.75% -16.1% -17.67% -38.51% -59.01% -50.99%

For the past year PerkinElmer Inc. had bullish trend while Cytosorbents Corporation had bearish trend.


PerkinElmer Inc. beats on 8 of the 13 factors Cytosorbents Corporation.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates through two segments, Discovery and Analytical Solutions and Diagnostics. The Discovery and Analytical Solutions segment develops and provides analytical technologies, solutions, and services that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, food, lubricant, petrochemical, and polymer industries; and laboratory services. This segmentÂ’s offers a suite of solutions, including reagents, liquid handling systems, and detection and imaging technologies that enable scientists to enhance life sciences research and drug discovery processes. Its research portfolio includes a range of systems consisting of imaging, detection, and extraction instrumentation for use on in vitro, ex vivo, and in vivo models, analysis hardware, and software; and a range of consumable products, including drug discovery and research reagents. The Diagnostics segment provides early detection for genetic disorders from pregnancy to early childhood, as well as flat panel X-ray detectors and infectious disease testing for the diagnostics market. This segment also develops technologies that enable and support sample-to-sequencer workflow using next-generation DNA sequencing for applications in oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. The company also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, it is developing CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, the company is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. It has collaboration with Aferetica srl to develop PerLife ex-vivo organ perfusion system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is headquartered in Monmouth Junction, New Jersey.